Evidence map›Paper›PMID 18486283›Full record

ArticleVaccine2008

Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.

Ruth H Florese, Roger W Wiseman, David Venzon, Julie A Karl, Thorsten Demberg, Kay Larsen, Leon Flanary, V S Kalyanaraman, Ranajit Pal, Fausto Titti and 6 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Ruth H FloreseVaccine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Roger W Wiseman
David Venzon
Julie A Karl
Thorsten Demberg
Kay Larsen
Leon Flanary
V S Kalyanaraman
Ranajit Pal
Fausto Titti
L Jean Patterson
Megan J Heath
David H O'Connor
Aurelio Cafaro
Barbara Ensoli
Marjorie Robert-Guroff
National Institutes of Health · USIstituto Superiore di Sanità · ITAdvanced Bioscience Laboratories (United States) · USNational Cancer Institute · USOregon National Primate Research Center · USUniversity of Wisconsin–Madison · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 1985 to 2011
$106.7M
Development of a Vaccine for HIVAIDS: Cellular ImmunityZIABC011062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$12.8M
HUMORAL AND CELLULAR IMMUNE RESPONSES TO HUMAN AND NONHUMAN PRIMATE RETROVIRUSESZ01BC005536 · NCI · BASIC SCIENCES · PI ROBERT-GUROFF, MARJORIE · 1996 to 2007
$4.1M
Nonhuman Primate Reagent ResourceN01AI40088 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · 2008 to 2010
$2.7M
BIOSTATISTICS AND DATA MANAGEMENT SECTIONZ01SC007202 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI STEINBERG, SETH M · 1996 to 2008
$1.5M
SIV-Specific CD8+ T-Cell in Mauritian Cynomolgus MacaquesR21AI068488 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI O'CONNOR, DAVID H. · 2006 to 2007
$507k
Intramural NIH HHS Z01 BC005536NCRR NIH HHS P51 RR000167NIAID NIH HHS 1 R21 AI 068488-01A2NIAID NIH HHS N01 AI015431NIAID NIH HHS N01 AI040088NIAID NIH HHS N01 AI 15431NIAID NIH HHS N01 AI 40088NIAID NIH HHS R21 AI068488NIH HHS P51 OD011106
6 · The paper itself

Abstract

Protection afforded by HIV Tat-based vaccines has differed in Indian rhesus and Mauritian cynomolgus macaques. We evaluated native Tat and Ad-HIVtat priming/Tat-boosting regimens in both species. Both vaccines were immunogenic. Only the Ad-tat regimen modestly reduced acute viremia in rhesus macaques after SHIV(89.6P) challenge. Confounding variables uncovered in Mauritian macaques included significant associations of susceptibility to infection with MHC class IB and class II H2 and H5 haplotypes, and resistance to infection with class IB haplotypes H3 and H6. Although protection here was limited, Tat-based vaccines incorporating other HIV components have shown greater efficacy. Combination strategies should be further explored.

Indexed as

Disease SusceptibilityHaplotypesAIDS VaccinesAnimalsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIMacaca fascicularisMacaca mulattaSimian Acquired Immunodeficiency Syndrometat Gene Products, Human Immunodeficiency VirusViral LoadViremiaAIDS VaccinesHistocompatibility Antigens Class IHistocompatibility Antigens Class IItat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID18486283
PMCPMC2577850
OpenAlexW1971990483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.